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In this podcast, we talk to Professor Richard Legro about the recommendations for the diagnosis and treatment of
polycystic ovary syndrome (PCOS) based on clinical practice guidelines and discuss the challenges of diagnosis
PCOS at specific age groups. The controversies associated with treatment of PCOS, including therapies for infertility
as this is a problem commonly observed in PCOS subjects, are highlighted together with future directions on the
topic.
The podcast for this interview is available at. http://www.biomedcentral.com/content/supplementary/s12916-
015-0299-2-s1.mp3
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Richard S. Legro, MD, is Professor in the Department
of Obstetrics and Gynecology at Penn State University
College of Medicine in Hershey, Pennsylvania, USA. He
graduated from Mount Sinai School of Medicine in New
York, NY, completed his residency at Magee Womens
Hospital at the University of Pittsburgh, and received his
fellowship in reproductive endocrinology at the University
of Southern California in Los Angeles, CA.
His research and clinical practice are primarily focused
on polycystic ovary syndrome (PCOS) diagnosis, treat-
ment, and genetic/environmental causes. He established
one of the first clinics devoted to the treatment of women
with PCOS at the M.S. Hershey Medical Center. Dr Legro
is currently an investigator in an ongoing Genome Wide
Association Study (GWAS) in PCOS and is the lead in-
vestigator of the multicenter U.S. National Institutes of
Health (NIH)-sponsored trials, Pregnancy in Polycystic
Ovary Syndrome I and II. He is the head of the steering
committee on several multicenter infertility trials currently
underway in China, including PCOSAct, a trial of clomi-
phene and acupuncture in women with PCOS. He has
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and books in the field of reproductive endocrinology. He is
additionally on the editorial boards for Endocrine Reviews
and Endocrinology and is an Associate Editor for Seminars
in Reproductive Medicine and Fertility and Sterility. He has
received several awards including the Presidential Achieve-
ment Award from the Society for Gynecologic Investiga-
tion (Figure 1).
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http://www.biomedcentral.com/content/supplementary/
s12916-015-0299-2-s1.mp3.Edited transcript
You’re a leading expert in reproductive endocrinology,
particularly in PCOS. Can you explain why you decided
to specialize in this particular endocrine condition?
This has had a lot to do with my mentors. These included
Dr David Guzick where I was a resident in Pittsburgh, and
Dr Roger Lobo in Los Angeles with whom I did my fel-
lowship. I subsequently was a junior faculty member here
with Dr Andrea Dunaif who is a reproductive and medical
endocrinologist who really educated me in all facets of the
syndrome. I think what attracted me to it is how little we
understand it and how afflicted the patients are. It is a dif-
ficult syndrome because we do not have good treatments
for a lot of their complaints, but it is rewarding in thatan Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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treating it –helps a lot of women, because it certainly is the
most common endocrinopathy in the developed world.
You’ve been a lead author for the Endocrine Society
Clinical Practice Guidelines on PCOS that was published in
JCEM in 2013. As we understand, this provides evidence-
based recommendations for the diagnosis and treatment
of PCOS. Can you describe the proposals outlined in these
guidelines for diagnosing the condition?
We recommended that the so-called Rotterdam criteria
should be used to diagnose PCOS. Those criteria are
based on finding two of the three cardinal features that
characterize PCOS. The first is hyperandrogenism which
is androgen excess and diagnosed either on the basis of a
clinical sign, such as hirsutism. This includes some mid-
line body hair, primarily on the lip, lower lip, and midline
between the breasts and the escutcheon that tracks up to
the umbilicus. Hyperandogenism can also be diagnosed
on the basis of elevated circulating levels of androgens.
The androgen that is most commonly used is testosterone,
but androstenedione may also be useful. This is particu-
larly helpful for populations that do not manifest hirsut-
ism. Specifically, this tends to be the Chinese, Japaneseand Korean populations that do not have a lot of apparent
hirsutism but have evidence of circulating androgen levels
comparable to that found in Caucasian cohorts.
In addition to hyperandrogenism, the second is ovulatory
dysfunction, and that can be manifested as oligomenorrhea
or infrequent menstruation. Sometimes this is observed as
secondary amenorrhea or total lack of periods for a while.
The third component is a characteristic of the appearance
of the ovaries known as the polycystic ovary. It is a mis-
nomer because the ovary really is not polycystic but it con-
tains a lot of very small follicles, that are the size of a
quarter inch or less, that develop into ovulatory follicles.
This enlarges the ovary with lots of follicles and usually in-
creases the central stoma, a central portion of the ovary
that is solid. This appearance of the polycystic ovary is the
third sign.
If you have two or three of the conditions indicated
above, you qualify for the diagnosis of polycystic ovary
syndrome. We relied on a workshop that had been held
and sponsored by the National Institutes of Health
(NIH), that upheld the expert consensus based Rotter-
dam criteria. One of the things we wanted to focus more
on was treatment rather than diagnosis, so we went with
the conventional opinion [for diagnosis]. Everyone should
be aware though that there is a lot of controversy on what
the proper diagnostic criteria are. Certainly I would say
the main criticism of Rotterdam criteria is that it can in-
clude subjects who have no hyperandrogenism. Thus, a
woman can have irregular periods and polycystic ovaries.
It appears that these women have a different prognosis
than the women with hyperandrogenism. Specifically,
these women tend to have less insulin resistance, less
glucose intolerance, less lipid abnormalities, and prob-
ably are more likely to be normal weight.
All the criteria agree that you should exclude common
conditions that may mimic some of the signs and symp-
toms of polycystic ovary syndrome. Thus, women should
be screened for thyroid dysfunction, prolactin excess,
and the onset of non-classical congenital adrenal hyperpla-
sia. In rare cases, where there are signs of virilization or
Cushingoid signs, women should be screened for these
other causes of severe androgen excess like an androgen-
secreting tumor or, in the case of the Cushingoid symp-
toms, should be screened for Cushing’s Syndrome. Thus,
all the guidelines agree that one should exclude conditions
that may mimic polycystic ovary syndrome.
Are there any specific challenges regarding the diagnosis
of PCOS associated with specific age groups – so the
adolescent or menopausal women?
In regards to the question about the specific challenges as-
sociated with adolescent and menopausal women, I think it
is difficult or nearly impossible to diagnose it in adolescent
and menopausal women. The reason for that is puberty
Legro BMC Medicine  (2015) 13:64 Page 3 of 5very much mimics the signs and symptoms of polycystic
ovary syndrome. Puberty is really characterized by the
awakening of the adrenal gland, and that contributes to
the formation of body hair in the pelvic region, and also
the awakening of the ovary, which results in the comple-
tion of puberty, development of secondary sexual charac-
teristics, such as breast development. The initial period is
characterized by relative androgen excess, much like poly-
cystic ovary syndrome.
Similarly, it is well known that girls, after they have their
first period (termed menarche) can have periods within
the first three years of relative oligo-ovulation and infre-
quent menses. Obviously it varies for different popula-
tions; some girls can normalize almost immediately after
menarche and other girls have a longer period of ovulatory
normalization.
The third characteristic is the polycystic ovary and what
really characterizes menarche is the appearance of mul-
tiple small antral follicles. It is very easy to confuse a poly-
cystic ovary with what we would call a multi-cystic ovary.
In prevalence studies, as many as 50 to 60 percent of nor-
mal girls who are teenagers will have what is called a po-
lycystic ovary by current diagnostic criteria. It is very
difficult to diagnose this in adolescence because there is a
tendency to over diagnose the condition. Additionally, I
think part of it is observing and not giving a girl a label
that she might not really have. Patience is required, I
think, to make this diagnosis. As you know, patience does
not characterize 21st century medicine. Thus I think that
it is being over diagnosed in adolescents right now.
In terms of menopausal women, I think what is the
most difficult thing is recall of menses which is highly
inaccurate. A woman who has gone through meno-
pause – for her to recall what her menstrual cycle was
like as much as 20 years prior – is difficult. It has been
shown that women with PCOS tend to develop more
regular menses as they age, and by age I am talking
about as they approach their late 30s and 40s, when
they appear to have more regular ovulations. Thus, the
natural history of polycystic ovary syndrome may be
that it resolves in this age range, and certainly during
the perimenopause, which is a period of five-to-seven
years prior to and surrounding menopause.
The other thing that characterizes menopause is that,
much like adolescence, it is a period of relative androgen
excess. Thus, with loss of ovarian follicles, there is loss
of the production of estrogen by these ovarian follicles,
but the ovarian stroma still produces androgen. Thus,
menopause per se almost qualifies, as every menopausal
woman could be diagnosed with PCOS, at least on the
basis of biochemical hyperandrogenemia (and cessation
of menses). Therefore, it tends to be a diagnosis that I
do not think I would make for the first time either in an
adolescent or in a menopausal woman.We’ve focused on the diagnosis of PCOS. If we move on
to the category of treatment of PCOS, can you describe
the recommendations made in the Clinical Practice
Guidelines that aim to improve treatment?
One of the take-home messages was to focus on the
complaint of the patient. The complaints can be variable.
If a patient presents with a primary complaint of hirsut-
ism, then one should certainly treat the hirsutism. If the
primary complaint is infertility, one should treat the in-
fertility. If the primary complaint is a menstrual disorder,
either oligo-ovulation, infrequent bleeding, frequent
bleeding or menorrhagia (heavy and prolonged menses),
then one should treat that complaint.
Unfortunately, treatments vary according to complaints.
To give you an example, for infertility, where we tend to
induce ovulation, there is really no treatment that induces
ovulation that also adequately treats hirsutism. Thus, we
often have to put hirsutism on the back burner while we
treat infertility. Similarly, most treatments for hirsutism
involve suppression of the ovaries and suppression of any
possibility for ovulation. It is difficult to primarily treat hir-
sutism and secondarily hope for resumption of ovulation
fertility.
Thus, several of the clinical practice guidelines focus on
what many of us feel is the sine qua non of the syndrome,
which is hyperandrogenism. The best treatment for female
hyperandrogenism is some form of hormonal suppression.
This would include hormonal contraception – obviously
birth control pills are used the most commonly – but
there is also a contraceptive patch and a vaginal ring.
There are also contraceptive formulations that are primar-
ily a progestin and injections and implants of progestin
can be used to suppress ovarian hyperandrogenism.
That’s really interesting in terms of the variability in
treatment. Are there any controversies associated with
the treatment of PCOS?
I would say that the primary controversy is one which
goes back to my training with a medical endocrinologist
and reproductive endocrinologist and one that still has
not been sorted out. This controversy is on what extent
polycystic ovary syndrome is a metabolic disorder. If the
women have been shown to be insensitive to the effects of
insulin, they often compensate with over-secretion of insu-
lin. Clearly in the periphery, the skeletal muscle is very re-
sistant to the action of insulin. This certainly predisposes
them to Type 2 diabetes and metabolic syndrome and,
questionably, to cardiovascular diseases. Certainly, they
have increased cardiovascular disease risk.
The other school of thought says that polycystic ovary
syndrome is primarily a reproductive disorder with in-
appropriate communication of the brain and pituitary
with the ovary. If one can get these systems in sync you
can have a normal ovulatory woman.
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proach this with – either the metabolic or reproductive
schools – then the appropriate therapies should be chosen.
The reproductive school certainly recommends the use of
hormonal contraceptives to suppress hyperandrogenism,
or the use of oral agents that affect estrogen action – so
primarily clomiphene, which is an estrogen-receptor in-
hibitor – to treat infertility. The metabolic school focuses
more on trying to improve insulin action. Metformin tends
to be the first choice by that school for many complaints,
both from a metabolic aspect as well as treating hyperan-
drogenism. Metformin does lower circulation androgens
and improves ovulation rate. Many use it also as a fertility
drug. However, it does not appear to be as good as clomi-
phene or letrozole (an aromatase inhibitor).
Another approach is lifestyle modification, with an
emphasis on weight loss as a means of improving the
metabolic picture. I think one of the things we outlined
in the guideline, and also in two meta-analyses that were
published concurrently in the same year in the Journal
of Clinical Endocrinology and Metabolism, was that we
found that, while certainly lifestyle therapy was associated
with improvements in glycemic parameters like weight,
there was not much that we could say about hyperandro-
genism. While certainly, we did not want to go against any
recommendations that an obese woman should undergo
lifestyle modifications to improve her diabetes and cardio-
vascular risk, it is difficult to say that that is going to im-
prove their PCOS symptoms. Here, PCOS is primarily
defined on the basis of reproductive parameters.
Similarly with metformin, much like lifestyle improves
glycemic parameters, it lowers testosterone, but is prob-
ably weight neutral in most studies. It is hard to advocate
this as an effective first-line treatment for the primary
complaints that these women present with: hirsutism, in-
fertility and menstrual disorder. Metformin just does not
work as well as, for instance, the oral contraceptive pill or
oral ovulation induction agents like clomiphene or letro-
zole. Thus, metformin probably should take a back burner
compared to the other treatments in the guideline. This
has created a lot of controversy and we did our best to
defend our recommendations and I think we did.
Clearly, these are comprehensive guidelines for the
treatment and diagnosis of PCOS and you have touched
upon this earlier – how it compares with the Rotterdam
criteria and the NIH recommendations – but how also
does it compare with previous Endocrine Society ones?
When the Endocrine Society does develop guidelines, we
carefully review other guidelines. There were many other
guidelines that were relevant to this, including the treat-
ment of hirsutism, the amelioration of cardiovascular risk
factors and the diagnosis of Cushing’s disease. Thus, we
referenced these other guidelines in ours and we do notreally tread on their territory; we defer to them and echo
any of their diagnostic recommendations. This, however,
was the first Endocrine Society guideline for polycystic
ovary syndrome. We were inventing the wheel, at least the
polycystic ovary syndrome wheel.
You also mentioned earlier about fertility as a problem in
women with PCOS, so let us discuss the recent trial that
you published in NEJM. This trial compares the use of
letrozole and clomiphene for infertility in PCOS. Can you
briefly describe the findings of that trial and how you think
this might inform future therapies for infertility in women
with PCOS?
We performed a double-blind multi-center controlled trial,
testing letrozole versus clomiphene for infertility in women
with polycystic ovary syndrome. The hypothesis was that
letrozole (an aromatase inhibitor) might be superior for the
outcome of live birth. Again, that is what patients who are
infertile want: a live birth. We thought an aromatase in-
hibitor might recruit fewer follicles than clomiphene.
Clomiphene is an infertility drug associated with an
eight-to-ten-fold increased risk of multiple pregnancies.
Certainly from a public health perspective, given the
morbidity – especially from pre-term delivery of multiple
pregnancies – this was definitely an outcome we wanted
to avoid. There also were data showing that an aromatase
inhibitor might have more favorable effects on the endo-
metrium and aid implantation after ovulation.
In our trial, we showed that women who used letrozole
had a 44 percent greater chance of a live birth compared
to clomiphene. This is a fairly significant difference. It is
actually about a 10 percent absolute increase in the preg-
nancy rate in women who had undergone our treatment,
which was five cycles of treatment with either clomiphene
citrate or letrozole. Indeed, while not significant, we found
that the multiple pregnancy rate was 7.4 percent with
clomiphene and 3.9 percent with letrozole. This was a sec-
ondary outcome and, while it was not significant, one
needs a trial that was probably about five times as big to
detect that difference in rate. However, we are optimistic
that lowering the multiple pregnancy rate might be a
beneficial side-effect of letrozole.
However, one of the concerns about letrozole was that
there might be an increased risk of birth defects, com-
pared to clomiphene. One of the things that has been
well documented in sub-fertile women is that they do
have a slightly higher rate of birth defects than women
who conceive spontaneously. We found that the rates of
birth defects were comparable between letrozole and
clomiphene and, actually, both were below what we
would expect in an infertile population. Thus, we were
reassured about that. However, like any trial like this
which we think will change our practice, replication of
these results is needed. Clomiphene has been really the
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rather a remarkable finding.
As we now draw to the close of this interview, can you
just tell us what you think are the most promising future
directions for diagnosing and treating PCOS?
Certainly in diagnosis, there has been a lot of research
trying to look at an endocrine serum marker that might
identify women with a tendency towards polycystic ovary
syndrome. Probably the most promising serum marker is a
hormone called anti-Müllerian hormone (AMH), which
roughly correlates with a number of small antral follicles.
Thus, this may be a useful blood test especially in younger
women where an ultrasound may be unwanted and inva-
sive and one that all practitioners could use, not just gyne-
cologists who have easy access to trans-vaginal ultrasound.
I think the jury is still out on that and we have to see more.
Another promising marker is our genetic markers that are
being identified through genetic studies and genome-wide
association studies. I think we have to validate these
markers prospectively, and that work is being done.
In terms of the treatment of PCOS, I think there is a
lot of interest now in developing oral drugs that might
perturb the way the brain and the pituitary communicate
with the ovary. I think a lot of these drugs may be very
useful for the treatment of polycystic ovary syndrome.
Another big question and one that I am writing up the
results right now – is what to do with obese women with
PCOS who want to get pregnant? How much should we
focus on lifestyle modification and weight loss prior to
treatment and how much we should just proceed directly
to treatment. We really need prospective trials that test a
lifestyle modification versus a controlled alternate treat-
ment to see what the benefits might be in terms of im-
proving pregnancy outcomes in both mother and infant.
Where can I find out more?
See references [1-10].
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